Actively Recruiting

Early Phase 1
Age: 18Years - 24Years
All Genders
Healthy Volunteers
NCT06489249

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

Led by University of Iowa · Updated on 2025-12-15

24

Participants Needed

2

Research Sites

111 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

CONDITIONS

Official Title

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

Who Can Participate

Age: 18Years - 24Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 to 24 years of age
  • No history of e-cigarette use (control) OR current use with at least 6 months history of e-cigarette use (chronic use)
Not Eligible

You will not qualify if you...

  • Current or past use of tobacco cigarettes
  • Use of stimulant drugs
  • Presence of skin diseases
  • Cardiovascular disease
  • Diagnosed or suspected liver or metabolic diseases including diabetes
  • Use of statins or other cholesterol-lowering medications
  • Use of antihypertensive medications
  • Current pregnancy or breastfeeding
  • Blood pressure greater than or equal to 140 mmHg systolic and/or 90 mmHg diastolic
  • Allergy to materials used during the experiment
  • Known allergies to salsalate or other study drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Iowa Bioscience Innovation Facility

Iowa City, Iowa, United States, 52242

Actively Recruiting

2

University of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

Loading map...

Research Team

A

Anna Stanhewicz, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use | DecenTrialz